Spectranetics price target raised to $30 from $24 at Stifel Stifel increased its price target on Spectranetics after the company announced positive results from its EXCITE ISR clinical trial. The firm sees the results as a major milestone for Spectranetics and keeps a Buy rating on the shares.
Spectranetics sees FY15 EPS (20c)-(10c), consensus (12c) Sees FY15 revenue $258M-$265M, consensus $274.36M. 2015 projected revenue includes reduced revenue in the range of $1.5M-$2M, or approximately 1%, due to the declining exchange rate of euros in relation to U.S. dollars. Vascular Intervention revenue growth is anticipated to be in the range of 41% to 46%. This includes AngioSculpt revenue of $62M-$66M and ISR revenue of approximately $15M-$20M. EBITDA is anticipated to be in the range of $12.3 million to $16.3 million. Gross margin is expected to increase by 50 to 100 basis points in 2015. Gross margin guidance for 2014 is 74.5% to 75%. Research, development and other technology expenses are expected to be approximately 15.5% to 16.0% of revenue, an increase over 2014 guidance of 14.5%, based on continued product development and clinical trial investments.